Strategic Investment Expansion at Ain Sokhna
Eng. Waheed Atteek, Chief Executive Officer of Ateco Pharma Egypt, has outlined the company’s latest investment expansion plans currently underway at its manufacturing facility in Ain Sokhna, emphasizing that these expansions represent a core pillar of the company’s strategy to increase production capacity and maximize export revenues in the coming period.
New Production Lines: Phase Two and Three
Atteek explained that the company has successfully completed the arrival and commissioning procedures for the production lines included in the second and third phases of its expansion plan, which was announced at the beginning of 2025. He noted that the implementation of these phases comes at a critical time, in line with the growing local and international demand for intravenous (IV) medical solutions.
Doubling IV Solutions Capacity and Product Expansion
He added that the new expansions aim to double the company’s production capacity of IV solutions to meet rising market demand, in addition to expanding the production of injectable ampoules and ophthalmic drops. This will enhance the company’s ability to supply the local market while strengthening its export presence in regional markets, in line with the state’s strategy to support the pharmaceutical industry and secure essential healthcare supplies.
High-Demand Products and Portfolio Flexibility
The CEO highlighted that the introduction of new production lines enables Ateco Pharma to launch high-demand pharmaceutical products, including small-volume IV ampoules and single-dose eye drops. This expansion increases production flexibility and enhances the competitiveness of the company’s product portfolio.
Installation Progress and 2026 Operational Launch
Atteek confirmed that all equipment for the second and third expansion phases has already arrived at the factory site, and that technical teams have begun installation works according to the approved timeline, in preparation for full operational launch during the first quarter of 2026.
Three Years of Operations and Accelerated Growth
He noted that the completion of these expansion phases coincides with the company’s third anniversary since the start of operations and production at the Ain Sokhna facility, reflecting the efficiency of planning, speed of execution, and the company’s ability to achieve advanced growth milestones within a short timeframe.
Export Performance and International Reach
Regarding exports, Atteek stated that Ateco Pharma recorded approximately USD 5 million in IV solution exports during 2025. He reaffirmed the company’s position as the largest exporter of IV medical solutions in Egypt, with products currently reaching more than 13 Arab and African countries. He expects exports to account for up to 60% of total production once the new lines become operational.
Upcoming Product Registrations
In parallel, the company is finalizing the registration of a new range of pharmaceutical products scheduled to be announced in 2026, supporting the coverage of market gaps locally and reinforcing international expansion plans.
Manufacturing Leadership and Global Quality Standards
Atteek also pointed out that Ateco Pharma is the largest pharmaceutical manufacturer within the Suez Canal Economic Zone. He emphasized that the newly introduced production lines were carefully selected in collaboration with the German-Swiss company Rommelag, reflecting Ateco Pharma’s commitment to applying the highest global quality standards in IV solution manufacturing.
Long-Term Expansion Roadmap
He stressed that the current expansion plan represents one phase of a long-term growth roadmap, noting that the company is already preparing for additional expansion stages aimed at further strengthening production capacity, supporting the healthcare sector, and contributing to the availability of critical medicines in line with national priorities.
A New Phase of Growth and Industry Legacy
Atteek concluded by stating that the current expansions mark a new launch point in Ateco Pharma’s growth journey. The arrival of advanced equipment lays the foundation for a new industrial phase, while the anticipated start of operations in 2026 signals a new era of self-sufficiency and export growth—enhancing healthcare security at both regional and international levels.
He added that the Atteek family has a long-standing legacy in the IV solutions industry, with the group founded in 1985 by Eng. Mohamed Atteek, Chairman of the Group, who established a strong industrial base that has played a key role in solidifying the company’s leadership position in this vital sector.
